Stock Traders Buy High Volume of Put Options on Teva Pharmaceutical Industries (NYSE:TEVA)

Teva Pharmaceutical Industries Limited (NYSE:TEVA) was the target of unusually large options trading activity on Monday. Stock investors acquired 37,691 put options on the stock. This represents an increase of approximately 38% compared to the typical daily volume of 27,275 put options.

Teva Pharmaceutical Industries Trading Up 0.9 %

TEVA opened at $22.42 on Wednesday. Teva Pharmaceutical Industries has a 12 month low of $10.34 and a 12 month high of $22.50. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.57. The stock has a 50-day moving average of $17.89 and a 200 day moving average of $17.56. The firm has a market cap of $25.40 billion, a P/E ratio of -26.38, a P/E/G ratio of 0.99 and a beta of 0.79.

Wall Street Analysts Forecast Growth

TEVA has been the subject of several recent analyst reports. StockNews.com downgraded Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 18th. JPMorgan Chase & Co. raised their target price on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research note on Monday, October 21st. Barclays boosted their price target on shares of Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 18th. Finally, UBS Group raised their price objective on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $20.88.

Insider Transactions at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, EVP Christine Fox sold 19,388 shares of the stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total value of $327,075.56. Following the completion of the sale, the executive vice president now owns 44,104 shares in the company, valued at approximately $744,034.48. This represents a 30.54 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.55% of the company’s stock.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Several large investors have recently modified their holdings of TEVA. Sanctuary Advisors LLC increased its position in Teva Pharmaceutical Industries by 1.9% during the third quarter. Sanctuary Advisors LLC now owns 35,129 shares of the company’s stock valued at $601,000 after acquiring an additional 664 shares during the last quarter. Sequoia Financial Advisors LLC boosted its stake in shares of Teva Pharmaceutical Industries by 0.7% during the 3rd quarter. Sequoia Financial Advisors LLC now owns 112,380 shares of the company’s stock worth $2,025,000 after purchasing an additional 805 shares during the period. DGS Capital Management LLC lifted its stake in Teva Pharmaceutical Industries by 6.8% in the third quarter. DGS Capital Management LLC now owns 13,627 shares of the company’s stock worth $246,000 after purchasing an additional 872 shares during the last quarter. Smithfield Trust Co boosted its position in shares of Teva Pharmaceutical Industries by 55.7% during the third quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock valued at $50,000 after buying an additional 980 shares during the period. Finally, Signaturefd LLC grew its stake in shares of Teva Pharmaceutical Industries by 16.9% during the third quarter. Signaturefd LLC now owns 7,583 shares of the company’s stock valued at $137,000 after buying an additional 1,094 shares during the last quarter. Institutional investors own 54.05% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.